-

Biological Dynamics to Present at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit

Wednesday, August 10, 2022 at 1:00 p.m. ET / 10:00 a.m. PT

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at their earliest stages, today announced that the company will participate at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

Dr. Paul Billings, CEO and Kevin Han, CFO are scheduled to participate in a fireside chat with UBS analysts on Wednesday, August 10th at 1:00 p.m. ET / 10:00 a.m. PT.

The company will discuss commercial launch plans for its first assay, an early-stage pancreatic cancer detection test, using enriched exosomal protein biomarkers on the company’s proprietary Verita™ isolation platform. Last month, in July 2022, this platform received the Audience Choice Award for the Disruptive Technology Competition at the 2022 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL.

To join the live webcast, visit Biological Dynamics’ website: https://biologicaldynamics.com/company-events. Following the presentation, the webcast recording will be available for replay.

About Biological Dynamics

Biological Dynamics, Inc. is a biotechnology company committed to improving global health outcomes by detecting diseases at their earliest stages. Our proprietary Verita™ platform simplifies access to biomarkers, nanoparticles, and nucleic acids, enabling differentiated multiomic applications. We are applying our proprietary methods with machine learning to detect several diseases, including cancer, in blood and other bodily fluids, at our CAP/CLIA accredited clinical laboratory in San Diego. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.

Contacts

Kevin Han
Chief Financial Officer
kevin.han@biodyn.io

Industry:

Biological Dynamics, Inc.

Release Versions
English

Contacts

Kevin Han
Chief Financial Officer
kevin.han@biodyn.io

More News From Biological Dynamics, Inc.

Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory. Using blood-based exosome samples enriched on the proprietary ExoVerita instrument, the ExoVita Pancreas assay measures specific exosomal...

Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC). The collaboration will test retrospective samples from over 200 patients starting this month. The ExoVerita™ platform is being investigated at NYU Langone Health, among other premier instituti...

Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

SAN DIEGO--(BUSINESS WIRE)--Biological Dynamics, a company developing and commercializing its ExoVeritaTM platform for early disease diagnostics, announced today that Harmeet Dhani, MD, MSc, Medical Director will present at the Precision Medicine World Conference (PMWC) in Santa Clara, Calif. Dr. Dhani’s PMWC showcase presentation on January 26th is part of the Clinical Utility of Liquid Biopsies track. The track focuses on how liquid biopsy technologies facilitate detection of early-stage canc...
Back to Newsroom